JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

Search

Becton Dickinson and Co

Chiusa

SettoreSettore sanitario

185.78 1.25

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

185.31

Massimo

185.87

Metriche Chiave

By Trading Economics

Entrata

27M

330M

Vendite

104M

5.3B

P/E

Media del settore

33.913

38.156

EPS

3.35

Rendimento da dividendi

2.23

Margine di Profitto

6.259

Dipendenti

70,000

EBITDA

93M

546M

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+8.32% upside

Dividendi

By Dow Jones

Rendimento da dividendi

Media del settore

2.23%

2.50%

Utili prossimi

7 ago 2025

Prossima data del Dividendo

30 set 2025

Prossima data del' Ex Dividendo

8 set 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-15B

50B

Apertura precedente

184.53

Chiusura precedente

185.78

Notizie sul Sentiment di mercato

By Acuity

16%

84%

20 / 375 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Very Strong Bearish Evidence

Becton Dickinson and Co Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

14 lug 2025, 14:26 UTC

Acquisizioni, Fusioni, Takeovers

Becton Dickinson Biosciences & Diagnostics Unit to Merge With Waters Corp. in $17.5 Billion Deal -- 2nd Update

14 lug 2025, 11:08 UTC

Acquisizioni, Fusioni, Takeovers

Becton Dickinson Unit to Combine With Waters Corp. in $17.5 Billion Deal -- Update

14 lug 2025, 10:37 UTC

Acquisizioni, Fusioni, Takeovers

Becton Dickinson Unit to Combine With Waters Corp. in $17.5 Billion Deal

1 mag 2025, 11:18 UTC

Utili

Becton 2Q Net Down, Warns of Tariff Hit on 2025 EPS

15 lug 2025, 18:32 UTC

Acquisizioni, Fusioni, Takeovers

Waters Corp. Deal for Becton Dickinson Unit a Long-Term Play With Some Risks -- Analysis

15 lug 2025, 18:31 UTC

Acquisizioni, Fusioni, Takeovers

Waters Deal for Becton Unit Pairs Near-Term Risks With Possible Long-Term Rewards, Analysts Say

14 lug 2025, 16:12 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Waters Closer to Thermo Fisher, Danaher With Becton Dickinson Unit -- Market Talk

14 lug 2025, 15:06 UTC

Acquisizioni, Fusioni, Takeovers

Waters Stock Is Falling on Deal to Combine With Becton Dickinson Unit -- Barrons.com

14 lug 2025, 14:11 UTC

Acquisizioni, Fusioni, Takeovers

Becton Dickinson Biosciences & Diagnostics Unit to Merge With Waters Corp. in $17.5B Deal -- 2nd Update

14 lug 2025, 10:53 UTC

Acquisizioni, Fusioni, Takeovers

Becton Dickinson Unit to Combine With Waters Corp. in $17.5B Deal -- Update

14 lug 2025, 10:22 UTC

Acquisizioni, Fusioni, Takeovers

Becton Dickinson Unit to Combine With Waters Corp. in $17.5B Deal

14 lug 2025, 10:22 UTC

Acquisizioni, Fusioni, Takeovers

Waters To Assume About $4 Billion Incremental Debt >WAT BDX

14 lug 2025, 10:22 UTC

Acquisizioni, Fusioni, Takeovers

Becton Dickinson to Get $4 Billion Cash Distribution Prior to Closing >WAT BDX

14 lug 2025, 10:21 UTC

Acquisizioni, Fusioni, Takeovers

Waters Holders to Own 60.8% of Combined Company, Becton Dickinson Holders to Own 39.2% >WAT BDX

14 lug 2025, 10:20 UTC

Acquisizioni, Fusioni, Takeovers

Waters, Becton Dickinson: Combined Company to Have About $9 Billion Revenue, $3.3 Billion Adjusted Ebitda >WAT

14 lug 2025, 10:19 UTC

Acquisizioni, Fusioni, Takeovers

Correct: Waters, Becton Dickinson See About $290 Million Revenue Synergies by Year Five >WAT BDX

14 lug 2025, 10:19 UTC

Acquisizioni, Fusioni, Takeovers

Waters, Becton Dickinson See About $345 Million Annualized Ebitda Synergies by 2030 >WAT BDX

14 lug 2025, 10:18 UTC

Acquisizioni, Fusioni, Takeovers

Waters, Becton Dickinson See About $290 Revenue Cost Synergies by Year Five >WAT BDX

14 lug 2025, 10:18 UTC

Acquisizioni, Fusioni, Takeovers

Waters, Becton Dickinson See About $200 Million Cost Synergies by Year Three >WAT BDX

14 lug 2025, 10:17 UTC

Acquisizioni, Fusioni, Takeovers

Waters: Becton Dickinson Deal Doubles Total Addressable Market to About $40 Billion >WAT

14 lug 2025, 10:16 UTC

Acquisizioni, Fusioni, Takeovers

Waters, Becton Dickinson Deal Structured as Reverse Morris Trust >WAT BDX

14 lug 2025, 10:16 UTC

Acquisizioni, Fusioni, Takeovers

Waters, Becton Dickinson Deal Valued at About $17.5 Billion >WAT BDX

14 lug 2025, 10:15 UTC

Acquisizioni, Fusioni, Takeovers

Waters to Combine With Becton Dickinson's Biosciences & Diagnostic Solutions Business >WAT BDX

14 lug 2025, 10:15 UTC

Acquisizioni, Fusioni, Takeovers

Waters and BD's Biosciences & Diagnostic Solutions Business to Combine

1 mag 2025, 10:33 UTC

Utili

Becton Dickinson Cuts FY25 Adj EPS View on Tariff Impact

1 mag 2025, 10:33 UTC

Utili

Becton Dickinson FY25 Adj EPS View Includes an Estimated Tariff Impact of Approximately 25c

1 mag 2025, 10:32 UTC

Utili

Becton Dickinson Sees FY25 Organic Rev Growth Guidance of 3.0% to 3.5% >BDX

1 mag 2025, 10:32 UTC

Utili

Becton Dickinson Narrows FY25 View To Rev $21.8B-$21.9B >BDX

1 mag 2025, 10:31 UTC

Utili

Becton Dickinson Intends To Invest $2.5 B in U.S. Manufacturing Capacity Over the Next 5 Years >BDX

1 mag 2025, 10:31 UTC

Utili

Becton Dickinson: Taking 'Decisive Mitigation Actions to Navigate the Current Macro Environment' >BDX

Confronto tra pari

Modifica del prezzo

Becton Dickinson and Co Previsione

Obiettivo di Prezzo

By TipRanks

8.32% in crescita

Previsioni per 12 mesi

Media 200.73 USD  8.32%

Alto 255 USD

Basso 172 USD

Basato su 13 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Becton Dickinson and Co - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

13 ratings

4

Acquista

9

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

167 / 206.99Supporto e resistenza

A breve termine

Very Strong Bearish Evidence

A termine intermedio

Weak Bearish Evidence

A lungo termine

Weak Bearish Evidence

Sentiment

By Acuity

20 / 375 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove rialziste molto forti

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Becton Dickinson and Co

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; and prefillable drug delivery systems. The BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.